A miracle child and an Aussie Nobel Prize winner. The five biggest science discoveries of 2025

Multiple 2025 scientific breakthroughs outlined have material implications for long-term sectoral winners: AI-driven protein design saw US biotech Absci dose the first patients with an AI-designed antibody for inflammatory bowel disease, building on AlphaFold’s transformational protein-folding advances. Gene editing delivered an early clinical success in a newborn (Baby KJ) using CRISPR delivered in lipid nanoparticles with reported clinical improvement within six months, while climate-tech advances include a 1989-discovered molecular carbon-sponge now being applied and James Webb data suggesting possible biosignatures on exoplanet K2-18b. A Google Quantum preprint cut the estimated qubit requirement to factor 2048-bit RSA to ~1 million noisy qubits, flagging a nearer-term cybersecurity risk that could reshape encryption-dependent markets.

Analysis

Market structure: Winners are platform-scale AI/cloud incumbents (GOOGL/GOOG) who own the compute, models and datasets that accelerate protein design and quantum research; specialist biotech firms (ABSI) benefit from AI-enabled discovery but face binary clinical risk. Losers include legacy encryption services that depend on RSA without post-quantum upgrades and small-cap biotechs lacking AI moats. Higher sustained demand for GPUs/TPUs and cloud services should push pricing power toward hyperscalers and drive capex in semiconductors and rare-earth supply chains over 12–36 months.

Risk assessment: Tail risks include a faster-than-expected quantum break of RSA within 1–5 years (high impact, low prob), major clinical failure for AI-designed therapeutics (near-term binary), and aggressive AI/biotech regulation (6–24 months). Hidden dependencies: AI protein success is contingent on proprietary datasets, compute availability and IP licensing; quantum threat depends on engineering advances, not just theory. Key catalysts: ABSI clinical readouts (next 6–12 months), Google quarterly AI/quantum disclosures (next 1–4 quarters), NIST/National announcements on post-quantum cryptography over 12–24 months.

Trade implications: Tactical allocation favors asymmetric exposure to GOOGL (platform + quantum research) and defensive plays in cybersecurity (ETF HACK or CRWD) as a hedge. For ABSI, prefer option-defined risk (calendar/vertical spreads) rather than outright equity; limit total biotech directional exposure to single-digits of risk capital. Cross-asset: expect modest upward pressure on long-term real yields if tech capex accelerates, and higher volatility in FX/crypto around major cryptography news.

Contrarian angle: The market may underprice the multi-year service revenue upside as AI-designed drugs move from discovery to licensing—favor long-duration calls on hyperscalers rather than spot biotech equities. Conversely, quantum-encryption fear could be overhyped in the short term: buying cybersecurity exposure now at modest size (1–2% portfolio) and selling near-term overreactions on legacy software names could capture mean reversion. Historical parallel: genomics hype cycle—big winners were platforms and data owners, not every discovery company.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in GOOGL (or GOOG) via 12–18 month LEAPS (e.g., 12–18 month ITM calls or buy-and-hold equity) to capture AI protein-design tailwinds and quantum/IP optionality; trim if shares rise >25% within 6 months or after a materially positive quarterly AI/quantum disclosure.
• Allocate 1% of risk capital to ABSI via a 6–9 month call spread (buy near-OTM call, sell higher strike) sized so max loss = 1% portfolio; target event: early clinical biomarker readout in 6–12 months. Close or convert to equity only on positive safety/efficacy signals.
• Buy 1–2% exposure to cybersecurity (ETF HACK or CRWD long) as a hedge against encryption disruption; increase to 3–4% if NIST or major governments accelerate post-quantum standards within 12 months or if Gidney/Google publish further practical timelines.
• Establish a pair trade: long GOOGL (2%) / short a diversified small-cap biotech basket (e.g., equal-weight small-cap biotech ETF or IBB small-cap tilt, 1–2%) to capture platform capture of downstream biotech value. Rebalance if dispersion in biotech index exceeds 30% relative to GOOGL over any 3-month window.
• Monitor: (a) ABSI trial milestones and FDA filings over next 6–12 months; (b) Google quarterly AI/quantum updates and any published qubit roadmap in next 1–4 quarters; (c) NIST/PQC announcements in 12–24 months. If quantum timelines shorten materially (public roadmap to >100k qubits within 12 months), rotate 1–2% from equities into short-dated protection (index puts) on financials/consumer tech most exposed to legacy encryption.